Pharming Group/$PHAR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pharming Group
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Ticker
$PHAR
Sector
Primary listing
Employees
404
Headquarters
Website
Pharming Group Metrics
BasicAdvanced
$981M
-
-$0.01
0.59
-
Price and volume
Market cap
$981M
Beta
0.59
52-week high
$17.08
52-week low
$7.50
Average daily volume
13K
Financial strength
Current ratio
2.795
Quick ratio
2.039
Long term debt to equity
49.579
Total debt to equity
53.569
Interest coverage (TTM)
1.91%
Profitability
EBITDA (TTM)
26.37
Gross margin (TTM)
89.31%
Net profit margin (TTM)
-2.41%
Operating margin (TTM)
5.78%
Effective tax rate (TTM)
344.42%
Revenue per employee (TTM)
$840,000
Management effectiveness
Return on assets (TTM)
2.85%
Return on equity (TTM)
-3.70%
Valuation
Price to revenue (TTM)
28.964
Price to book
3.47
Price to tangible book (TTM)
8.02
Price to free cash flow (TTM)
326.688
Free cash flow yield (TTM)
0.31%
Free cash flow per share (TTM)
0.045
Growth
Revenue change (TTM)
22.44%
Earnings per share change (TTM)
-34.85%
3-year revenue growth (CAGR)
18.86%
10-year revenue growth (CAGR)
28.33%
3-year earnings per share growth (CAGR)
-25.00%
10-year earnings per share growth (CAGR)
-6.22%
Bulls say / Bears say
Total revenues jumped 26 percent year-over-year to US$93.2 million in Q2 2025, fueled by a 28 percent increase in RUCONEST revenues to US$80.4 million and a 15 percent rise in Joenja revenues to US$12.8 million, highlighting strong commercial execution (Nasdaq).
Management raised full-year 2025 revenue guidance to US$335 million–US$350 million (from US$325 million–US$340 million), indicating confidence in continued volume growth and pricing leverage (GlobeNewswire).
Pharming extended its global reach by launching Joenja in the U.K. with positive NICE reimbursement guidance and submitting a leniolisib NDA in Japan, setting up the company for meaningful international expansion (GlobeNewswire).
Despite Q2 profitability, Pharming posted a net loss of US$10.3 million for the first half of 2025, showing the company is still unprofitable on a half-year basis (GlobeNewswire).
Cash and cash equivalents fell to US$130.8 million as of June 30, 2025, down from US$169.4 million at the end of 2024, raising questions about the company’s cash runway given ongoing R&D and integration costs (GlobeNewswire).
Pharming’s pipeline outside of RUCONEST and Joenja is thin; with only KL1333 in the Phase II FALCON trial as a late-stage candidate, the company faces considerable clinical development risk before seeing further significant revenues (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharming Group stock?
Pharming Group (PHAR) has a market cap of $981M as of September 18, 2025.
What is the P/E ratio for Pharming Group stock?
The price to earnings (P/E) ratio for Pharming Group (PHAR) stock is 0 as of September 18, 2025.
Does Pharming Group stock pay dividends?
No, Pharming Group (PHAR) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Pharming Group dividend payment date?
Pharming Group (PHAR) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharming Group?
Pharming Group (PHAR) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.